{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-104304","form_type":"8-K","ticker":"SGMT","cik":"0001400118","company_name":"Sagimet Biosciences Inc.","filed_at":"2023-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.790914+00:00","generated_at":"2026-06-10T08:05:55.212033+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sagimet partner Ascletis enrolls 120 patients in Phase 3 trial of denifanstat for rGBM","bullets":["Ascletis completed enrollment of 120 patients in Phase 3 registration trial of denifanstat plus bevacizumab for recurrent glioblastoma.","Interim analysis of progression-free survival anticipated after sufficient events from the 120 subjects.","Sagimet expects FASCINATE-2 Phase 2b NASH biopsy results and Phase 1 hepatic impairment data in Q1 2024.","Denifanstat is an oral FASN inhibitor; Sagimet licensed China rights to Ascletis in January 2019."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-104304","json":"https://secwatch.observer/filing/0001104659-23-104304.json","markdown":"https://secwatch.observer/filing/0001104659-23-104304.md","text":"https://secwatch.observer/filing/0001104659-23-104304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923104304/0001104659-23-104304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1400118/000110465923104304/tm2327008d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:05:55.212033+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}